These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 11365275)

  • 21. Human immunodeficiency virus (HIV)-specific immune responses are generated with the simultaneous vaccination of a gp120-depleted, whole-killed HIV-1 immunogen with cytosine-phosphorothioate-guanine dinucleotide immunostimulatory sequences of DNA.
    Moss RB; Diveley J; Jensen FC; Gouveia E; Carlo DJ
    J Hum Virol; 2001; 4(1):39-43. PubMed ID: 11213932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The HIV vaccine pipeline, from preclinical to phase III.
    Schultz AM; Bradac JA
    AIDS; 2001; 15 Suppl 5():S147-58. PubMed ID: 11816163
    [No Abstract]   [Full Text] [Related]  

  • 24. HIV gp160 vaccine gene therapy (Wyeth-Lederle Vaccines-Malvern).
    Drugs R D; 1999 Jun; 1(6):451-2. PubMed ID: 10566081
    [No Abstract]   [Full Text] [Related]  

  • 25. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens.
    Bazhan SI; Belavin PA; Seregin SV; Danilyuk NK; Babkina IN; Karpenko LI; Nekrasova NA; Lebedev LR; Ignatyev GM; Agafonov AP; Poryvaeva VA; Aborneva IV; Ilyichev AA
    Vaccine; 2004 Apr; 22(13-14):1672-82. PubMed ID: 15068850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Status and current strategies of HIV vaccine development].
    Wild J; Wagner R
    Internist (Berl); 2003 Jun; 44(6):711-8. PubMed ID: 14567107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polygene DNA vaccine induces a high level of protective effect against HIV-vaccinia virus challenge in mice.
    Shinoda K; Xin KQ; Jounai N; Kojima Y; Tamura Y; Okada E; Kawamoto S; Okuda K; Klinman D; Okuda K
    Vaccine; 2004 Sep; 22(27-28):3676-90. PubMed ID: 15315847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
    Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
    Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DNA vaccination of macaques by a full genome HIV-1 plasmid which produces noninfectious virus particles.
    Akahata W; Ido E; Shimada T; Katsuyama K; Yamamoto H; Uesaka H; Ui M; Kuwata T; Takahashi H; Hayami M
    Virology; 2000 Sep; 275(1):116-24. PubMed ID: 11017793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current strategies and limitations of HIV vaccines.
    Kawalekar OU; Shedlock DJ; Weiner DB
    Curr Opin Investig Drugs; 2010 Feb; 11(2):192-202. PubMed ID: 20112169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A review of vaccine research and development: the human immunodeficiency virus (HIV).
    Girard MP; Osmanov SK; Kieny MP
    Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 neutralizing antibodies: how full is the bottle?
    Moore JP; Burton DR
    Nat Med; 1999 Feb; 5(2):142-4. PubMed ID: 9930854
    [No Abstract]   [Full Text] [Related]  

  • 33. Nucleic acid-based immunization against HIV-I: induction of protective in vivo immune responses.
    Wang B; Boyer JD; Ugen KE; Srikantan V; Ayyaroo V; Agadjanyan MG; Williams WV; Newman M; Coney L; Carrano R
    AIDS; 1995; 9 Suppl A():S159-70. PubMed ID: 8819582
    [No Abstract]   [Full Text] [Related]  

  • 34. Subtype AE HIV-1 DNA and recombinant Fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques.
    De Rose R; Chea S; Dale CJ; Reece J; Fernandez CS; Wilson KM; Thomson S; Ramshaw IA; Coupar BE; Boyle DB; Sullivan MT; Kent SJ
    Vaccine; 2005 Mar; 23(16):1949-56. PubMed ID: 15734067
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conference on advances in AIDS vaccine development--1993. Summary: correlates of HIV Immunity Working Group.
    Sheppard H; Bridges SH; Mathieson BJ; Walker MC; Weinhold K
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S171-6. PubMed ID: 7865294
    [No Abstract]   [Full Text] [Related]  

  • 37. Envelope-based HIV vaccines.
    Donnelly JJ; Barnett SW; Dorenbaum A; Stamatatos L
    Science; 2002 Aug; 297(5585):1277-8; author reply 1277-8. PubMed ID: 12194177
    [No Abstract]   [Full Text] [Related]  

  • 38. Status report on HIV vaccine development.
    Cheonis N
    BETA; 1999; 12(4):40-8, 53. PubMed ID: 11367251
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current issues in the development of a vaccine to prevent human immunodeficiency virus: insights from the society of infectious diseases pharmacists.
    Sahloff EG
    Pharmacotherapy; 2005 May; 25(5):741-7. PubMed ID: 15899735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.
    Weniger BG; Anglin IE; Tong T; Pensiero M; Pullen JK;
    Vaccine; 2018 Jan; 36(4):427-437. PubMed ID: 29174315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.